Post-traumatic stress disorder (PTSD) is a trauma and stressor related disorder that causes severe distress or impairs the ability to function following exposure to a traumatic event. PTSD is a global health crisis that affects over 700 million people and presents significant challenges for clinicians regarding diagnosis and effective treatment options.
40 years of research identifies key genes which are linked to disruptions in the stress response system that increases a person's risk of PTSD.
TruGenomix Health will revolutionize the screening of PTSD by developing the first genetic blood test to detect predisposition to PTSD, facilitating earlier diagnosis and improved outcomes.
Better risk prediction leads to earlier intervention
Genomic information facilitates personalized therapy and leads to improved outcomes
Early intervention and personalized therapy leads to reduced readmission and lower healthcare costs